Skip to main content

Month: June 2025

Hapbee Announces CDN$1.5M Private Placement Led by Company Executive; Announces Appointment of Ahsan Ashraf as Chief Technology Officer

VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) — Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or the “Company”), the digital wellness technology company, is pleased to announce a non-brokered private placement consisting of up to 15,070,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of up to $1,507,000 (the “Offering”). Each Unit will consist of one subordinate voting common share of the Company (a “Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable for one additional Share of the Company at a price of $0.20 CAD for two years from the date of issuance. Building upon the company’s significant growth over the past two fiscal quarters, the proceeds from the Offering will be strategically...

Continue reading

Clairvest Reports Fiscal 2025 Fourth Quarter and Year End Results

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Clairvest Group Inc. (TSX: CVG) today reported results for the fourth quarter and year ended March 31, 2025 and events which occurred subsequent to year end. (All figures are in Canadian dollars unless otherwise stated) HighlightsMarch 31, 2025 book value was $1,251.6 million or $88.30 per share compared with $1,234.3 million or $86.78 per share as at December 31, 2024 and $1,176.3 million or $80.16 per share as at March 31, 2024 Net income for the fourth quarter was $20.7 million or $1.46 per share as the fair value of certain investments increased Net income for fiscal 2025 was $122.0 million or $8.47 per share. During fiscal 2025, Clairvest had $46.1 million of net realized gains from the realization of four investments and $44.8 million of net investment gains on its remaining private...

Continue reading

CVB Financial Corp. Announces 143rd Consecutive Quarterly Cash Dividend

Ontario, CA, June 25, 2025 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced a twenty cent ($0.20) per share cash dividend with respect to the second quarter of 2025. This dividend was approved at the Company’s regularly scheduled Board of Directors meeting held on June 25, 2025. The quarterly dividend will be payable on or about July 24, 2025 to shareholders of record as of July 10, 2025. “We are pleased to announce our 143rd consecutive quarterly cash dividend paid to our shareholders,” said David A. Brager, President and Chief Executive Officer. Corporate OverviewCVB Financial Corp. (“CVBF”) is the holding company for Citizens Business Bank. CVBF is one of the 10 largest bank holding companies headquartered in California with greater than $15 billion in total assets. Citizens Business Bank is consistently...

Continue reading

ROHM Launches an Isolated Gate Driver IC Optimized for High-Voltage GaN Devices

Isolated Gate Driver ICOptimized for driving 600V-class high-voltage GaN HEMTsSanta Clara, CA and Kyoto, Japan, June 25, 2025 (GLOBE NEWSWIRE) — ROHM Semiconductor today announced the development of the  BM6GD11BFJ-LB, an isolated gate driver IC optimized for driving 600V-class high-voltage GaN HEMTs. When combined with GaN devices, this driver enables stable operation under high-frequency, high-speed switching conditions – contributing to greater miniaturization and efficiency in high-current applications such as motors and server power supplies. As global energy consumption continues to grow, energy-saving initiatives have become a shared global priority. Motors and power supplies alone are estimated to account for approx. 97% of the world’s total electricity consumption. Achieving higher efficiency in these systems...

Continue reading

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce an update to its previously announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company (the “Common Shares”). Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of...

Continue reading

Apollo Names Celia Yan as Head of Hybrid for Asia Pacific

HONG KONG, June 26, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Celia Yan has joined the firm as a Partner and Head of Hybrid for Asia Pacific. Based in Hong Kong, Yan will lead the expansion of Apollo’s hybrid platform across the region, building on the firm’s momentum in delivering flexible, tailored capital solutions across private markets. Apollo’s hybrid business focuses on delivering creative, partnership-driven solutions that sit between traditional debt and equity. We provide solutions that help companies fund growth initiatives, generate liquidity and deleverage balance sheets, among other bespoke applications. In this newly created role, Yan will drive origination, execution and growth for Apollo’s hybrid strategies in Asia Pacific. Yan brings over 20 years of industry experience and extensive private...

Continue reading

Hapbee Issues Clarification of June 24, 2025 Press Release on Q1 2025 Financial Results

Following a 198% sales surge in Q4, Hapbee added 191% revenue growth in Q1 2025 while reducing operating expenses by 62% VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) — Hapbee Technologies Inc. (TSXV: HAPB | OTCQB: HAPBF), (“Hapbee” or the “Company”), the digital wellness technology company pioneering the science of bio-streaming, announces this clarification of its earlier press release dated June 24, 2025. This clarification is being issued at the request of the Canadian Investment Regulatory Organization (CIRO). Building on the momentum of Q4 2024, Hapbee entered 2025 with continued growth in sales – delivering meaningful growth in sales, notable reductions in operating expenses, and strategic improvements across its product and platform ecosystem. The Company’s Q1 performance results underscore Hapbee’s...

Continue reading

Freddie Mac Issues Monthly Volume Summary for May 2025

MCLEAN, Va., June 25, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today posted to its website its Monthly Volume Summary for May 2025, which provides information on Freddie Mac’s mortgage-related portfolios, securities issuance, risk management, delinquencies, debt activities and other investments. Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability and affordability in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn more: Website | Consumers | LinkedIn | Facebook| X | Instagram | YouTube MEDIA CONTACT: Fred Solomon703-903-3861Frederick_Solomon@FreddieMac.com INVESTOR CONTACT: Mahesh Lal571-382-3630

Continue reading

Vor Bio Announces $175 Million Private Placement

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses. Private Placement Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Vor Bio will issue prefunded warrants (the “Warrants”) to purchase an aggregate of 700,000,000 shares of common stock at a purchase price of $0.25 per Warrant. The PIPE included a syndicate of world-class investors including Vor Bio’s existing stockholder RA Capital Management, as well as Mingxin Capital, Forbion, Venrock Healthcare...

Continue reading

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

–Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties -Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio, Inc. (Nasdaq: VOR) and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.